Product logins

Find logins to all Clarivate products below.


Urological Devices | Market Insights | Japan | 2022

The deferral or cancellation of nonessential procedures due to the COVID-19 pandemic negatively impacted the Japanese urological device market in 2020; however, the market will show a strong recovery in 2021. Following the short-term impact of the global pandemic, the market will continue to expand through 2030, driven by the increasing prevalence of kidney conditions among Japan’s large aging population. However, market growth will be hindered by the complex regulatory environment in Japan, which will inhibit the availability and uptake of new premium-priced devices to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in Japan across an 11-year period.

Related Medtech Insights Reports

Report
Laparoscopic Devices – Market Insights – Japan
The Japanese laparoscopic device market will expand modestly through 2034, driven by rising demand for MIS procedures among the country’s rapidly aging population. Additionally, the adoption of…
Report
Diagnostic Imaging Systems – Market Insights – Japan
Japan’s diagnostic imaging system market will experience slow growth through 2034, driven by continuous technological advancement and rising hospital demand for efficient, patient-centric imaging…
Report
Urological Devices – Market Insights – United States
Fueled by persistent obesity rates, rising kidney stone prevalence, and an expanding aging population, the US urological device market will grow steadily through 2034. Growth will be supported by…
Report
Urological Devices – Market Insights – Japan
The Japanese urological device market will continue to expand through 2034, driven by the rising prevalence of risk factors for urological disorders, such as the growing burden of metabolic…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Japan
The Japanese EP mapping and ablation device market will experience moderate growth through 2034, supported by rising cardiac arrhythmia prevalence, broader treatment accessibility, and ongoing…